Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6124215 | Journal of Infection and Chemotherapy | 2011 | 5 Pages |
Abstract
We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24Â h (AUC0-24) to minimum inhibitory concentration (MIC) (AUC0-24/MIC) and the ratio of maximum plasma concentration (Cmax) to MIC (Cmax/MIC), which predict microbiological outcomes, and the Cmax/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa. Monte Carlo simulation was performed for 10000 cases using the pharmacokinetic data of patients with complicated UTIs and the LVFX MIC distributions for E. coli or P. aeruginosa clinical strains. The probabilities of achieving the AUC0-24/MIC target (66.2-67.9%) and the Cmax/MIC target (64.5-67.5%) to eradicate E. coli were similar among the 4 regimens. In eradication of P. aeruginosa, the 200-mg thrice-daily and the once-daily dose regimens produced higher probabilities of achieving the AUC0-24/MIC target (57.5%) and Cmax/MIC target (55.1%), respectively. For the probabilities of achieving the Cmax/MIC targets that prevent the emergence of fluoroquinolone resistance, the once-daily dose regimen (66.8%) did not differ from the other multiple-dose regimens (62.3-66.2%) in E. coli, whereas the former regimen (44.2%) was superior to the latter regimens (10.8-31.7%) in P. aeruginosa. The 500-mg once-daily dose regimen of LVFX, which produced the larger AUC0-24 and higher Cmax, could ensure the efficacy of eradication of uropathogens and reduce the risk of fluoroquinolone resistance selection in complicated UTIs.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Takashi Deguchi, Kensaku Seike, Mitsuru Yasuda, Tetsuro Matsumoto,